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Abstract: Previously, we have synthesized several series of compounds based on the  
5-aryl-2-aminoimidazole scaffold, which showed a preventive activity against microbial 
biofilms. We here studied the cytotoxicity of the most active compounds of each series. First, 
the cytostatic activity was investigated against a number of tumor cell lines (L1210, CEM 
and HeLa). A subset of monosubstituted 5-aryl-2-aminoimidazoles showed a moderate 
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safety window, with therapeutic indices (TIs) ranging between 3 and 20. Whereas 
introduction of a (cyclo-)alkyl chain at the N1-position strongly reduced the TI, introduction 
of a (cyclo-)alkyl chain or a triazole moiety at the 2N-position increased the TI up to 370. 
Since a promising application of preventive anti-biofilm agents is their use in anti-biofilm 
coatings for orthopedic implants, their effects on cell viability and functional behavior of 
human osteoblasts and bone marrow derived mesenchymal stem cells were tested. The  
2N-substituted 5-aryl-2-aminoimidazoles consistently showed the lowest toxicity and 
allowed survival of the bone cells for up to 4 weeks. Moreover they did not negatively affect 
the osteogenic differentiation potential of the bone cells. Finally, we examined the effect of 
the compounds on the survival of Caenorhabditis elegans, which confirmed the higher safety 
window of 2N-substituted 5-aryl-2-aminoimidazoles. 
Keywords: 5-aryl-2-aminoimidazole; biofilm inhibitor; toxicity; tumor cell lines; bone cells; 
Caenorhabditis elegans 
 
1. Introduction 
In the last decades it has become clear that microorganisms predominantly live as surface-associated 
communities, called biofilms, which are embedded in a self-produced exopolymeric matrix [1–4]. This 
is reflected by the observation by the U.S. National Institutes of Health that approximately 80% of all 
microbial infections are related to biofilms [5,6] and that biofilms are ubiquitous in the environment. 
Within biofilms microorganisms are generally well-protected against the influence of disinfectants, 
antibiotics [7] and the host immune system [8], and as a consequence biofilms are extremely difficult to 
eradicate [9]. As such, they cause major problems in medicine, agriculture, (food) industry and the 
household environment. Biofilm formation by Pseudomonas aeruginosa in the lungs of patients 
suffering from cystic fibrosis (CF) is one of the best studied examples of biofilm involvement in chronic 
infections. Because the bacteria assemble in biofilms, this chronic infection is often non-curable and 
eventually results in the death of CF patients [4,10].  
Given the extent of problems caused by biofilms, there has been a significant effort to develop novel 
anti-biofilm strategies [11,12]. One of the most promising approaches is the exploitation of compounds 
able to prevent or eradicate biofilms, without affecting the planktonic growth of the microorganisms. 
These specific anti-biofilm compounds are believed to be less prone to resistance development. 
Previously, we have developed and reported several series of specific anti-biofilm compounds, based on 
the 5-aryl-2-aminoimidazole (5-Ar-2AI) scaffold. As illustrated in Figure 1, these series include the 
mono-substituted 5-Ar-2AIs (1a) [13], N1-substituted 5-Ar-2AIs (1b) [13], 2N-substituted 5-Ar-2AIs 
(1c) [14], 4,5-di-substituted 2AIs (1a) [13], 1,4,5-trisubstituted 2AIs (1d) [15], and 2AI-triazole-conjugates 
(1e) [16]. These compounds show a preventive activity against biofilms of several Gram-positive and 
Gram-negative bacteria, as well as fungal species, and this in a range of environmental conditions. 
Previous studies indicated that the cytotoxicity of 2-aminoimidazole (2AI)-based compounds is 
strongly dependent on their substitution patterns. Several families of marine sponges produce 2AI-based 
compounds as a chemical defense mechanism to protect themselves against predators, fight-off 
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competition for space and resources and control surface fouling [17]. Many of these natural 2AIs are 
cytotoxic [18]. For example, girolline (2a, Figure 2), a 2AI isolated from the demosponge Peudaxinyssa 
cantharella, exhibits significant cytotoxicity in vitro against several tumor cell lines and in vivo against 
murine-grafted tumors, including P388 and L1210 leukemias, and solid tumors [19,20]. The 2AI-pyrrole 
alkaloids bromoageliferin (2b) and dibromoageliferin (2c), isolated from the demosponge Agelas conifer, 
were found to inhibit the calcium entry in PC12 cells [21]. Another 2AI-pyrrole compound, ageladine A 
(2d), isolated from the demosponge Agelas nakamurai, was shown to reduce angiogenesis in a model 
using mouse ES cells, by inhibiting matrix metalloproteinase 2 [22]. Also the 1,4,5-trisubstituted 2AI 
alkaloids naamine E (2f), C (2e), F (2g) and G (2h), the 1,2,4-trisubstituted 2AI isonaamidine E (2i) and 
the tetrasubstituted 2AIs naamidine H (2k) and I (2l), all isolated from the calcareous sponge Leucetta 
chagosensis, were cytotoxic to a variety of cell lines, including HMO2, HepG2, HeLa and mouse 
lymphoma cells [23–25]. Moreover, the tetrasubstituted 2AI naamidine A (2j), also isolated from  
L. chagosensis, was reported to potently inhibit epidermal growth factor-stimulated DNA synthesis in 
squamous cell tumors and cause A-431 cells to arrest in the G1 phase of the cell cycle [26,27]. While 
cytotoxicity against tumor cells is desired in anti-cancer applications, it should be avoided in  
anti-bacterial applications. Therefore, it is interesting to note that several studies indicated that the 
cytotoxic activity is not inherent to the 2AI-scaffold and can be counteracted by changing the 2AI 
substitution pattern. Watson et al., for example, found that the known natural product naamine A (2m), 
the C2-dehydrohydantoin deletion analogue of naamidine A, exhibits a markedly decreased ability to 
inhibit EGFR stimulated DNA synthesis [28]. Using GH4C1 rat pituitary and N2A mouse neuroblastoma 
cell lines, Melander et al. showed that the anti-biofilm compounds TAGE (2n) and CAGE (2o) lack the 
cytotoxicity of their parent molecule, bromoageliferin [29]. Moreover, they found that, although the 
three oroidin-derived anti-biofilm compounds DHS (2p), RA (2q) and SPAR (2r) lack toxicity against 
Caenorhabditis elegans, they show a differential effect on HaCaT keratinocyte cells, again pointing at 
the importance of the substitution pattern of the 2AI-scaffold [30]. 
Figure 1. Classes of 5-aryl-substituted 2-AI with anti-biofilm activity reported by our lab [13–16]. 
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Figure 2. Structures of 2-aminoimidazole (2AI) based compounds, previously tested  
for cytotoxicity. 
 
To define which of our 5-Ar-2AI-based anti-biofilm compounds are most promising for further 
development, we here aimed at the determination of the cytotoxicity of the most active compounds of 
each subclass. Although mammalian animal models have been a gold standard, they tend to be lengthy 
and expensive to study. We therefore tested the compounds in a battery of complementary in vitro 
cellular assays. To get a first idea of their cytotoxicity, the cytostatic activity of the compounds was 
tested against a number of commonly used tumor cell lines, i.e., murine leukemia L1210, human 
lymphocyte CEM, and human cervix carcinoma HeLa [31–33]. Cytostatic activity against multiple 
tumor cell lines can provide an indication of basal toxicity on fast growing tissue cells (e.g., mucosa, 
bone marrow, …) [34]. A promising application of specific, preventive anti-biofilm agents is their use 
in anti-biofilm coatings for implants, such as orthopedic implants. Since it is of great importance that the 
anti-biofilm compounds not be cytotoxic for bone tissue and do not negatively affect the osseointegrative 
potential of the implant, their effects on cell viability and functional behavior (differentiation potential) 
of two of the most relevant cell types represented in bone tissue (human osteoblasts and bone marrow 
derived mesenchymal stem cells) were also tested. Finally, we examined the effect of the compounds on 
the survival of C. elegans, a nonparasitic nematode species, which has become one of the most 
extensively studied model organisms. C. elegans is a valuable toxicity model since there is increasing 
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evidence that results obtained with C. elegans are predictive of outcomes in higher eukaryotes, both at 
the level of genetic and physiological similarity and at the level of actual toxicity data [35,36]. Indeed, 
many of the basic physiological processes and stress responses that are observed in higher organisms 
(e.g., humans) are conserved in C. elegans [37]. From these initial studies, promising subsets of 
compounds can be further subjected to more rigorous investigations.  
2. Results and Discussion 
2.1. Cytostatic Activity against Tumor Cell Lines 
To get a first idea of their cytotoxicity, a selection of the most active compounds of each subclass of 
5-Ar-2AIs was investigated for cytostatic activity against murine leukemia (L1210), human  
T-lymphocyte (CEM) and human cervix carcinoma (HeLa) cell lines. The IC50 was defined as the 
compound concentration required to inhibit cell proliferation by 50%. The therapeutic index (TI) was 
calculated as the ratio of the compound concentration producing toxicity (IC50) to the concentration 
needed to exert the desired ‘therapeutic’ effect on biofilms of Salmonella and Pseudomonas, indicated 
by the BIC50 (dose needed to prevent biofilm formation by 50%). The higher the therapeutic index, the 
broader the safety window of the compound.  
As shown in Table 1, the monosubstituted 5-Ar-2AIs have cytostatic IC50 values for all cell lines in 
the range of 15–150 µM. Comparison with the BIC50 for Salmonella biofilm inhibition indicates a 
reasonable safety window for compounds 2 and 4 (bearing resp. a chlorine and a nitro group at the  
5-aryl-ring), with TIs ranging between 3 and 6 for all cell lines, while compounds 1, 3 and 5 are toxic at 
concentrations overlapping with the Salmonella biofilm inhibitory concentrations [13]. In comparison 
with the BIC50 for Pseudomonas biofilm inhibition, compound 2 shows an interesting safety window 
(with TIs between 14 and 22), while compounds 3–5 have a moderate safety window (with TIs between 
1.5 and 7) and compound 1 is toxic at the biofilm inhibitory concentrations. 
We previously reported that introduction of an intermediate length n-alkyl or cycloalkyl chain at the 
N1-position of the 5-Ar-2AIs strongly enhances their anti-biofilm activity [13]. However, as indicated 
in Table 1, these modifications also strongly increase the cytotoxicity of the compounds. Indeed, all the 
N1-substituted 5-Ar-2AIs tested have IC50 values in the range of 3-9 µM. As a result these compounds 
generally have TI’s lower than 1, both with respect to Salmonella and Pseudomonas biofilm inhibition. 
Exceptions are compound 10 (N1-octyl-5-Ph-2AI), which has a moderate safety window with regard to 
Salmonella biofilm inhibition (TI’s between 2 and 2.5), and compounds 13 (N1-cyclo-octyl-5-Ph-2AI) 
and 15 (N1-octyl-5-[4-SMePh]-2AI), which have a moderate safety window with regard to Pseudomonas 
biofilm inhibition (TIs between 1.5 and 2.5) [13]. 
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Table 1. Cytostatic activity of 5-Ar-2AI subclasses against tumor cell lines, toxicity against C. elegans and anti-biofilm activity against bacterial strains. 
 
     IC50 a (µM) SD for IC50 (µM) BIC50 b (µM) 95% Confidence Interval for BIC50 %survival at 
25 µM de n° R4 R1 R2 R3 L1210 CEM HeLa L1210 CEM HeLa S. Typhimurium  P. aeruginosa S.Typhimurium  P. aeruginosa 
monosubstituted                      
1 H H H H 62.9 94.3 144.6 31.4 75.4 31.4 130.2 72.6 112.6–150.7 38.7–136.2 89.8 
2 4-Cl H H H 77.5 49.6 72.3 25.8 8.3 5.2 16 3.5 14.3–17.9 2.3–5.2 84.9 
3 4-Ph H H H 37.4 13.6 34.0 25.9 4.3 1.3 17.3 8.6 15.9–18.8 4.8–15.6 nd 
4 4-NO2 H H H 83.3 63.7 107.7 4.9 14.7 14.7 17.6 34.5 15.0–20.5 20.4–58.8 97.3 
5 4-Br H H H 10.1 13.9 21.8 2.5 9.7 1.7 47.9 3.2 36.6–62.8 2.3–4.5 90.6 
N1-substituted                      
6 H Oct H H 3.2 467.9 3.0 1.1 2.2 1.1 11.9 18.5 10.2–13.8 8.4–40.7 92.5 
7 4-Cl Oct  H H 3.9 356.8 4.5 1.3 0.7 1.0 5.9 4.0   3.0–5.2 86.6 
8 4-Cl Trd H H 7.2 6.4 4.5 0.3 1.9 3.5 19.5 33.9 11.1–34.5 15.0–76.4 nd 
9 4-Ph Hept H H 7.5 8.1 8.7 0.3 1.2 1.2 9.3 25.2 6.9–12.4  15.6–40.9 nd 
10 4-Ph Oct H H 7.8 8.3 6.6 1.2 0.0 1.4 3.3 8.9 1.2–9.0 3.5–22.5 nd 
11 4-Ph c-Pen H H 4.3 2.9 8.2 2.3 1.4 1.0 7.5 353.1 5.5–10.3 151.2–824.6 nd 
12 4-Ph c-Hept H H 8.1 5.4 6.6 1.5 4.2 3.9 ~12.5 6.6   2.9–14.7 nd 
13 4-Ph c-Oct H H 6.9 4.9 6.9 6.8 88.4 10.2 ~22.9 3.2   1.5–6.7 nd 
14 4-F Oct H H 3.5 7.3 8.6 0.0 2.4 1.0 ~10.8 4.9   3.8–6.2 nd 
15 4-SMe Oct H H 4.1 7.2 6.3 1.6 0.3 1.3 6.7 2.8 6.0–7.5 1.9–4.0 nd 
16 3-Br Oct H H 6.9 9.7 8.0 0.0 0.6 0.3 11.2 40.6 10.3–12.1 29.5–56.1 nd 
17 3,4-diCl m-MeOPhenethyl H H 6.9 8.6 6.6 1.3 0.1 0.6 >400 nd c     nd 
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Table 1. Cont. 
     IC50 a (µM) SD for IC50 (µM) BIC50 b (µM) 95% Confidence Interval for BIC50 %survival at 
25 µM d e n° R4 R1 R2 R3 L1210 CEM HeLa L1210 CEM HeLa S. Typhimurium P. aeruginosa S. Typhimurium P. aeruginosa 
2N-substituted                      
18 H H Bu H 46.4 667.4 19.5 0.0 92.9 4.6 25.3 31.8 23.3–27.6 21.3–47.3 nd 
19 H H i-Bu H 83.6 382.7 91.4 9.3 9.3 27.9 4.9 1.2 3.5–6.7 0.6 2.5 nd 
20 H H c-Pen H 27.3 293.3 27.3 11.0 10.1 3.5 52.9 33.8 42.4–66.1 23.9–47.7 98.1 
21 4-Cl H Bu H 40.0 374.6 34.7 12.0 11.2 2.0 nd nd     nd 
22 4-Cl H i-Bu H 336.3 297.3 171.5 92.1 0.0 104.1 2 0.9 1.6–2.5 0.5–1.8 97.6 
23 4-Cl H Pen H 22.0 322.9 19.8 14.0 4.2 0.8 >400 ~6.3     nd 
24 4-Cl H c-Pen H 35.5 591.0 28.8 3.4 11.5 22.9 4.4 13.5 4.0–4.8 9.0–20.5 100.1 
25 4-Br H Bu H 125.8 493.0 50.7 6.0 10.0 5.2 7.1 9.8 3.7–13.9 6.8–14.1 102.4 
26 4-Br H i-Bu H 31.7 306.0 22.6 2.8 20.1 1.6 2.9 1.2 2.6–3.4 0.6–2.3 nd 
27 4-Br H Pen H 14.9 375.2 16.3 10.4 14.0 1.6 3.1 10.2 2.0–5.0 2.9–35.9 nd 
28 4-Br H c-Pen H 32.7 673.6 32.7 3.3 26.1 6.5 12.1 7.2 6.5–22.5 4.4–12.0 nd 
29 3,4-diCl H c-Pen H 76.1 155.9 79.8 14.5 101.5 54.4 5.7 7.9 3.8–8.5 4.2–14.8 nd 
4,5-disubstituted            
30 H H H 4-OMePh 64.1 52.8 45.2 3.8 3.8 15.1 77.1 nd 60.6–98.0   nd 
31 H H H 4-ClPh 59.3 48.2 40.8 7.4 0.0 7.4 46.9 nd 35.2–62.5   nd 
32 4-Cl H H 4-MePh 12.3 10.2 9.5 2.1 1.4 1.8 12.9 nd 10.7–15.6   nd 
33 4-Cl H H 4-CF3Ph 41.5 35.5 26.1 3.0 3.0 2.1 10.8 nd 6.5–17.8   nd 
34 4-F H H amidophenyl 74.2 74.2 77.6 3.4 23.6 6.7 182.1 nd 116.6–284.4   nd 
1,4,5-trisubstituted            
35 4-Me Ben H p-PenOBn 8.6 8.4 14.8 0.7 0.9 9.8 10.3 27.4 8.0–13.3 12.32–60.78 nd 
2AI-triazole conjugates            
36 H H n = 2, R'= Ph H 221.0 452.6 72.9 115.0 302.7 9.1 36.5 >400 22.9–58.1   87.7 
37 H H n = 3, R' = Ph H 217.8 459.2 106.7 101.6 290.4 52.3 40.0 19.0 32.3–49.5 8.8–41.0 86.4 
38 4-OMe H n = 2, R' = 4-BrPh H 18.4 596.6 16.8 0.2 4.6 6.8 91.2 42.7 40.4–205.9 22.4–81.7 nd 
39 4-Br H n = 2, R' = c-Hex H 20.7 396.0 22.5 1.2 7.0 5.5 8.4 ~12.5 6.7–10.4   99.3 
40 4-Br H n = 2, R' = c-Pr H 43.9 33.6 67.1 2.6 20.7 10.3 2.0 71.6 1.4–2.9 21.8–234.8 82.6 
a IC50: compound concentration required to inhibit cell proliferation by 50%. The values represent the means of three repeats. Standard deviations are provided in Table S1; 
b BIC50: compound concentration required to prevent biofilm formation (at 25 °C) by 50%, as previously reported [13–16]. 95% confidence intervals are provided in Table 
S1; c TI: the ratio of the compound concentration producing toxicity (IC50) to the dose needed to exert the desired ‘therapeutic’ effect on biofilms (BIC50); d nd: not determined; 
e The % survival of the worms in the presence of anti-biofilm compounds was calculated after 7 days relative to their viability at day 0. The values represent the means of 
least two repeats. Standard deviations are provided in Table S1. 
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We also reported that introduction of an intermediate length alkyl chain (n-butyl, iso-butyl,  
cyclo-butyl, n-pentyl or cyclopentyl) at the 2N-position of the 5-Ar-2AIs can strongly increase their  
anti-biofilm activity [14]. Interestingly, these 2N-substituted 5-Ar-2AIs generally do not show a 
markedly increased cytotoxicity as compared to the mono-substituted 5-Ar-2AIs. On the contrary, the 
cytotoxicity is often even reduced, with IC50 values ranging between 15 and 600 µM. As a result the 
safety window of many of these compounds is strongly broadened. More specifically, all tested  
5-Ar-2AIs substituted with an iso-butyl group at the 2N-position have high TIs both with respect to 
Salmonella and Pseudomonas biofilm inhibition, irrespective of the nature of the R4 substituent  
(Figure 3). Especially compound 22, bearing an iso-butyl substituent at the 2N-position and p-chlorophenyl 
at the 5-position, has a very broad safety window with TIs in the range of 85 to 380. Also, all tested 
compounds derived from compound 5 (with p-bromo as R4 group) by introduction of an intermediate 
length alkyl chain at the 2N-position (i.e., compounds 25–28) have increased TIs (far higher than 10) 
with respect to Salmonella and/or Pseudomonas biofilm inhibition (Figure 4). Except for compounds 20 
and 23, which have TIs below 1, all other compounds tested show higher safety windows. This points to 
the potential of the 2N-alkyl-substituted 5-Ar-2AIs to be further explored and developed into safe  
anti-biofilm agents. It should be noticed that CEM cell cultures seem to be less sensitive to the 
antiproliferative activity of the 2N-substituted and 2AI-triazole conjugate derivatives, but not the other 
compounds, compared to L1210 and HeLa cell cultures. The molecular basis of this observation is 
currently unclear. 
Figure 3. Effect of introduction of an iso-butyl chain at the 2N-position (R2) of 5-Ar-2AIs, 
bearing H, Cl or Br at the para-position of the 5-phenylring (R4), on the therapeutic index 
(TI) with respect to Salmonella Typhimurium biofim inhibition (A) and Pesudomonas 
aeruginosa biofilm inhibition (B). 
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Figure 4. Effect of introduction of an intermediate length (cyclo-)alkyl chain (Bu, i-Bu, Pen, 
c-Pen) at the 2N-position of 5-(p-bromophenyl)-2-aminoimidazole (compound 5) on the 
therapeutic index (TI) with respect to Salmonella Typhimurium biofilm inhibition (A) and 
Pseudomonas aeruginosa biofilm inhibition (B). 
 
As previously reported, the 4,5-di-substituted 5-Ar-2AIs are active against biofilms at similar doses 
as the mono-substituted 5-Ar-2AIs [13]. As indicated in Table 1, also the cytotoxic activity occurs at 
similar concentrations, with IC50 values between 10 and 80 µM, resulting in similar TIs. Only  
compound 33, 4,5-substituted with a p-chlorophenyl and a p-trifluoromethylphenyl group, shows a 
moderate safety window with respect to Salmonella biofilm inhibition, with TIs between 2.4 and 3.8.  
The 1,4,5-trisubstituted compound 35 has therapeutic indices below 1 with respect to biofilm 
inhibition of both bacterial species, again demonstrating that introduction of an alkyl substituent at the 
N1-position does not improve the safety window [15]. 
Finally, a number of the most active 2AI-triazole conjugates were tested for cytotoxicity [16]. In these 
compounds a triazole moiety is coupled to the 2N-position of the 2AI-ring via an ethyl or propyl linkage. 
Although to a lesser extent than for the 2N-alkyl-substituted 2AIs, also the 2AI-triazole conjugates 
generally show an increased safety window with respect to Salmonella and/or Pseudomonas biofilm 
inhibition, as compared to the 2N-unsubstituted compounds, with TI values ranging between 2 and 50 
for compounds 36, 37, 39 and 40. Especially compound 40 shows a promising safety window with regard 
to Salmonella biofilm inhibition with TI values higher than 16 for all cell lines [16]. Triazole click 
chemistry provides an easy way to immobilize 2AIs to a surface, generating a triazole moiety between 
the 2AI and the surface. The present data indicate that this is not only an easy but also a safe method for 
2AI immobilization. 
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2.2. Effects on Viability and Functional Behavior of Bone Cells 
A promising application of specific, preventive anti-biofilm agents is their use in anti-biofilm coatings 
for implants, such as orthopedic implants. The osseointegrative properties of the implant are crucial for 
the long-term functional bone regeneration. Therefore it is of great importance that the applied  
anti-biofilm agents are not cytotoxic for osteoblasts (OB) and mesenchymal stem cells (MSC) and do 
not negatively affect the osseointegrative potential of the implant [38]. Therefore, we tested these 
features for a selection of three compounds displaying high TI’s, namely 22, 25 and 40, and compound 7, 
which was more toxic against the tumor cell lines. 
Figure 5. Effect of selected compounds (12.5 µM) on the proliferation and viability of 
osteoblasts (OB) and mesenchymal stem cells (MSC) after 2 h, 48 h and 6 days of exposure, 
as determined by trypan blue staining. Negative controls were cell culture medium and cell 
culture medium with 0.5% DMSO solvent background, positive control was 0.05% phenol 
to show a cytotoxic effect. % Proliferation is defined as: (total viable cells in treated 
sample/total viable cells in solvent control) × 100. % Viability is defined as: total viable cells 
(unstained)/total cells (stained + unstained) × 100. Bars and error bars represent resp. means 
and standard errors of 8 repeats. Significant differences (p < 0.05) with the negative solvent 
control are indicated with an asterix (*). 
 
Firstly, the effect of compounds 7, 22, 25 and 40 was tested on the proliferation (i.e., percentage of 
viable cells in treated sample compared to viable cells in solvent control) and viability (i.e., percentage 
of viable cells in treated sample compared to total number (viable and non-viable) of cells in treated 
sample) of OB and MSC in function of time. For each compound a dose of 12.5 µM was used, which is 
well above the BIC50 value of all compounds for Salmonella Typhimurium biofilm inhibition and  
P. aeruginosa biofilm inhibition (except for compound 40, which has a P. aeruginosa BIC50 of 72 µM). 
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Direct measurement of cell viability by trypan blue staining indicated that, after 48h exposure to  
12.5 µM of compound 7, the proliferation and viability of both cell types was strongly reduced as 
compared to the solvent control (>70% reduction, Figure 5). In contrast, compounds 22, 25 and 40  
(12.5 µM) do not or only slightly reduce the proliferation and viability of either of the two cell types 
after 48h and after 6 days of exposure. Compounds 22, 25 and 40 even allow survival of MSC and OB 
after 4 weeks of exposure. Consistently, MTT staining indicated a strongly reduced metabolic activity 
for both cell types (>80% as compared to the untreated controls) after 6 days exposure to 12.5 µM of 
compound 7, while compounds 22, 25 and 40 (12.5 µM, 6 days exposure) even slightly enhance the 
metabolic activity (results not shown). These results are in line with the results with the tumor cell lines 
and emphasize the potential of the 2N-substituted compounds 22, 25, 40 to be applied in anti-biofilm 
coatings for orthopedic implants. 
Next, the effect of compounds 22, 25 and 40, which showed the lowest toxicity against the bone cells 
and allowed survival of MSC and OB cells for more than 3 weeks, was tested with respect to the 
osteogenic differentiation potential of MSC and OB, as those two cell types are responsible for the 
production of new bone matrix within bone tissue. Calcium deposition was chosen as an indicator of the 
osteogenic phenotype, as it is the final and functional marker of osteoblast differentiation. As shown in 
Figure 6, none of the compounds does negatively affect the calcium deposition of either of the two cell 
types at 12.5 µM.  
Figure 6. Effect of selected compounds (12.5 µM) on the osteogenic differentiation potential 
of osteoblasts (OB) and mesenchymal stem cells (MSC) after resp. 3 and 5 weeks of 
exposure, as determined by measuring the amount of calcium deposition compared to the 
solvent control. Bars and error bars represent resp. means and standard errors of at least four 
repeats. The negative control contains no osteogenic supplements. The solvent control 
contains osteogenic supplements and a 0.5% DMSO background. Significant differences  
(p < 0.05) with the solvent control are indicated with an asterix (*). 
 
Interestingly, compound 22 even significantly (p < 0.05) induces the calcium deposition of both cell 
types, while compound 25 significantly induces the calcium deposition of MSC. This suggests that  
anti-biofilm coatings with these compounds might possibly even stimulate the osseointegrative potential 
of orthopedic implants. 
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2.3. Evaluation of the Toxicity against C. elegans 
The multicellular nematode worm C. elegans is regarded as one of the best multicellular models to 
understand the biology of all animals, including humans [39]. Therefore, we tested the effect of a variety 
of monosubstituted, N1-substituted and 2N-substituted 5-Ar-2AIs, as well as 2AI-triazole conjugates, on 
the survival of C. elegans (Table 1). Although the tested compounds include both compounds with a low 
cytotoxicity against the tumor cell lines (e.a. 22 and 25) and a higher cytotoxicity (e.a. 6 and 7), all 
compounds allow a survival of more than 80% of the C. elegans nematodes after 7 days exposure to a 
dose of 25 µM. As such, the tumor cell lines seem to be more sensitive to the 2AIs as compared to the 
multicellular C. elegans model. To further evaluate their safety window a selected number of compounds 
(1, 7, 22, 25 and 40) was tested at higher concentrations. As shown in Figure 7, none of the compounds 
significantly affect C. elegans survival at 100 µM. At a concentration of 200 µM, the mono-substituted 
5-Ar-2AI 1 and the 2N-substituted 5-Ar-2AIs 22, 25 and 40 do not significantly affect survival, while 
the N1-substituted 5-Ar-2AI 7 inhibits survival by more than 50%. This again points at the higher toxicity 
of the N1-substituted compounds. 
Figure 7. Effect of selected compounds (100 and 200 µM) on the survival of C. elegans, 
after 7 days of exposure. The % survival of the worms in the presence or absence (DMSO 
background) of anti-biofilm compounds was calculated after 7 days relative to their viability 
at day 0. Bars and error bars represent resp. means and standard errors of four repeats. 
Significant differences (p < 0.05) with the DMSO control are indicated with an asterix (*). 
 
3. Experimental Section 
3.1. Compound Preparation 
All compounds were synthesized according to our previous reported protocols [13–16], after which 
stock solutions in DMSO (20, 25 or 50 mM) were prepared.  
3.2. Cytostatic Activity against Tumor Cell Lines 
Murine leukemia (L1210), human T-lymphocyte (CEM) and human cervix carcinoma (HeLa) were 
suspended at 300,000–500,000 cells/mL of culture medium, and 100 µL of a cell suspension was added 
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to 100 µL of an appropriate dilution of the test compounds in 200 µL-wells of 96-well microtiter plates. 
After incubation at 37 °C for two (L1210), three (CEM) or four (HeLa) days, the cell number was 
determined using a Coulter counter. The IC50 was defined as the compound concentration required to 
inhibit cell proliferation by 50%. 
3.3. Cytotoxicity against Osteoblasts and Mesenchymal Stem Cells 
The cytotoxicity of the compounds was measured on cell cultures of two cell types represented in 
bone tissue, namely human osteoblasts (OB) and human bone marrow-derived mesenchymal stem cells 
(MSC). These tests were conducted according to ISO 10993-5 cytotoxicity standard. The cells were 
seeded in a 96-well plate at a density of 5000 cells/cm2 in cell culture media (Advanced DMEM, 10% 
FBS, 1× GlutaMAX, 0.05 mg/mL gentamicin) and allowed to attach overnight. The next day the test 
compounds (12.5 μM) and controls were added to the cells (negative controls were cell culture medium 
and cell culture medium with 0.5% DMSO background, positive control was 0.05% phenol to show a 
cytotoxic effect) and incubated for 2h, 48h and 6 days and at each time-point the numbers of viable and 
dead cells were determined by trypan blue staining, and the metabolic activity was determined with  
MTT staining. 
Trypan blue staining: the medium was removed from the wells, and 1/3 trypan blue in DMEM 
medium was added to the cells, incubated for 3 min, after which trypan blue was removed and DMEM 
medium was added to the wells. In each of four wells, two microscopy fields were counted for viable 
(transparent) and dead (blue) cells.  
MTT: the medium was removed from the wells and 100 μL of medium, supplemented with 10% 
serum and 0.5 mg/mL MTT was added to the cells. The cells were incubated overnight at 37 °C and 5% 
CO2. The next day the medium with MTT was removed and 100 μL acidic isopropanol was added. The 
cells were then centrifuged at 2300 g and 50 μL of the supernatant was transferred to a new 96-well 
plate. The absorbance was measured at 570 nm and the background was measured at 660 nm. Four wells 
per condition were examined. 
3.4. Calcium Assay for Determination of Osteogenic Differentiation Potential 
MSC and OB were cultured in osteogenic medium for 3 and 5 weeks, respectively. The experimental 
groups included a positive solvent control (osteogenic medium with 0.5% DMSO background), a 
negative control (medium without osteogenic supplements) and treated samples (osteogenic medium, 
0.5% DMSO background and 12.5 µM of test compound). Cell cultures were extracted by 5% 
trichloroacetic acid (500 μL per sample). O-Cresolphtalein complex was added (Calcium CPC 
LiquiColor Test®; Stanbio Laboratory, Boerne, TX, USA), and the calcium content was determined 
spectrophotometrically at 550 nm. 
To determine the DNA content, cells were washed with PBS, and 200 μL of digestion buffer  
(10 mM Tris, 1 mM EDTA, 0.1% Triton X-100, 0.1 mg/mL proteinase K) was added. Samples were 
incubated in digestion buffer overnight at 56 °C. The supernatants were drawn off and PicoGreen® dye 
(Molecular Probes, Eugene, OR, USA) was added to the samples in 1:1 ratio and read in a fluorescent 
plate reader (excitation 485 nm and emission 528 nm). DNA values were used to normalize the calcium 
content. Four wells per condition were examined, and two samples from each well were taken for each assay.  
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3.5. C. elegans Toxicity Test 
Eggs of a double mutant (glp-4Dsek-1D) of C. elegans were grown on NGM/OP50 agar plates (NGM 
agar plates on the surface inoculated with 100 µL of an overnight culture of OP50 Escherichia coli and 
stored at 4 °C until use) at 25 °C until all nematodes had reached the L4 stage. Worms were collected 
and washed with M9 buffer (3 g/L KH2PO4, 6 g/L Na2HPO4, 5 g/L NaCl, 1 mM MgSO4.). For toxicity 
testing, 40 to 50 worms were suspended in 250 μL M9 (supplemented with 10 µg/mL cholesterol,  
75 µg/mL ampicillin and 100 µg/mL kanamycin) buffer in each well of 24-well microtiter plates, in the 
presence or absence (0.5% DMSO control) of 25, 100 or 200 µM of the test compounds and grown for 
7 days at 25 °C. The percentage survival of the worms in the presence or absence of anti-biofilm 
compounds was calculated after 7 days relative to their viability at day 0. 
4. Conclusions 
To define which of our 5-aryl-2-aminoimidazole-based anti-biofilm compounds are the most 
promising for further development, we studied the cytotoxicity of the most active compounds of each 
subclass. With regard to the cytostatic effect on the tumor cell lines (L1210, CEM, and HeLa) the 
aminoimidazoles substituted with a (cyclo-)alkyl chain or a triazole moiety at the 2N-position showed 
the broadest safety window with TI’s up to 370. Consistently, the 2N-substituted 2-aminoimidazoles did 
not affect cell viability and functional behavior of bone cells (osteoblasts and mesenchymal stem cells) 
nor the viability of the model organism C. elegans. Therefore, from these initial studies, 2N-substituted 
5-aryl-2-aminoimidazoles seem to be most promising as anti-biofilm agents.  
Supplementary Materials 
Table S1 showing the cytostatic activity of 5-Ar-2AI subclasses against tumor cell lines,  
toxicity against C. elegans and anti-biofilm activity against bacterial strains is available at 
http://www.mdpi.com/1420-3049/19/10/16707/s1. 
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